Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Breakthrough cancer pain (BTcP) is a rapid onset, high intensity and short duration pain
episode, which takes place within stable background pain control. It significantly affects
the quality of life of patients with cancer and their ability to function normally. Rapid
onset opioids and immediate-release oral opioids (e.g. morphine sulfate, hydromorphone, and
oxycodone) are the standard treatment for BTcP. Because of the limited availability, high
cost, complicated titration and the high risks of overdosing with rapid-onset opioids, most
often the preferred choice of treatment is immediate-release oral opioids. However, this
approach might not always offer optimal speed for onset of action and duration to match the
rapid nature of an episode of BTcP. In order to seek a potential alternative to
immediate-release oral opioids, we are proposing to test the onset of action of PPP001 to
rapidly alleviate breakthrough pain in patients with cancer. We will also examine the safety
and the efficacy on pain intensity of PPP001 within this population.